STOCK TITAN

[SCHEDULE 13G/A] Arcturus Therapeutics Holdings Inc. Amended Passive Investment Disclosure

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

ARK Investment Management LLC and Catherine D. Wood report a 9.19% beneficial stake in Arcturus Therapeutics Holdings Inc. common stock. As of December 31, 2025, they together report ownership of 2,611,099 shares, with ARK holding sole voting and dispositive power over these shares.

Catherine D. Wood reports shared voting and dispositive power over the same 2,611,099 shares. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcturus. ARK Genomic Revolution ETF is noted as a client with an interest exceeding 5% of the class.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



ARK Investment Management LLC
Signature:/s/ Kellen Carter
Name/Title:Kellen Carter, Chief Compliance Officer
Date:02/03/2026
Catherine D. Wood
Signature:/s/ Catherine D. Wood
Name/Title:Catherine D. Wood, Chief Executive Officer, Chief Investment Officer
Date:02/03/2026
Arcturus Therape

NASDAQ:ARCT

ARCT Rankings

ARCT Latest News

ARCT Latest SEC Filings

ARCT Stock Data

209.41M
26.28M
7.88%
89.26%
19.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO